Paper41369447
Therapeutic Potential of Nanoscale Metal-Organic Frameworks in Hepatocellular Carcinoma.
Tutunchi H and 2 others. Nanomaterials (Basel), 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Therapeutic Potential of Nanoscale Metal-Organic Frameworks in Hepatocellular Carcinoma. Papers, record 41369447. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41369447
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References77
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31746153 | Photodynamic Therapy Combined with Antihypoxic Signaling and CpG Adjuvant as an In Situ Tumor Vaccine Based on Metal-Organic Framework Nanoparticles to Boost Cancer Immunotherapy. | Adv Healthc Mater | 2020 | https://conductscience.org/library/papers/31746153 | PubMed |
| 2 | 21115576 | The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. | Oncologist | 2010 | https://conductscience.org/library/papers/21115576 | PubMed |
| 3 | 40006592 | Drug Delivery Systems Based on Metal-Organic Frameworks for Tumor Immunotherapy. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40006592 | PubMed |
| 4 | 40890797 | Nanoscale metal-organic frameworks as a versatile platform for synergistic combination tumor therapy. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/40890797 | PubMed |
| 5 | 33283806 | Multifunctional metal-organic framework heterostructures for enhanced cancer therapy. | Chem Soc Rev | 2021 | https://conductscience.org/library/papers/33283806 | PubMed |
| 6 | 40734635 | Recent Developments in Nanoparticle-Hydrogel Hybrid Materials for Controlled Release. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40734635 | PubMed |
| 7 | 33277608 | Engineering precision nanoparticles for drug delivery. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33277608 | PubMed |
| 8 | 39852047 | Recent Advances in Metal-Organic Framework-Based Anticancer Hydrogels. | Gels | 2025 | https://conductscience.org/library/papers/39852047 | PubMed |
| 9 | 32909732 | A Hepatocellular Carcinoma Targeting Nanostrategy with Hypoxia-Ameliorating and Photothermal Abilities that, Combined with Immunotherapy, Inhibits Metastasis and Recurrence. | ACS Nano | 2020 | https://conductscience.org/library/papers/32909732 | PubMed |
| 10 | 37631285 | A Novel Platform of MOF for Sonodynamic Therapy Advanced Therapies. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37631285 | PubMed |
| 11 | 34255347 | Radiation therapy-associated toxicity: Etiology, management, and prevention. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/34255347 | PubMed |
| 12 | 32151012 | Metal Organic Frameworks as Drug Targeting Delivery Vehicles in the Treatment of Cancer. | Pharmaceutics | 2020 | https://conductscience.org/library/papers/32151012 | PubMed |
| 13 | 31996879 | A natural polysaccharide mediated MOF-based Ce6 delivery system with improved biological properties for photodynamic therapy. | J Mater Chem B | 2020 | https://conductscience.org/library/papers/31996879 | PubMed |
| 14 | 37569377 | A Comprehensive Review of Inorganic Sonosensitizers for Sonodynamic Therapy. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37569377 | PubMed |
| 15 | 31194910 | Cancer-Cell-Activated Photodynamic Therapy Assisted by Cu(II)-Based Metal-Organic Framework. | ACS Nano | 2019 | https://conductscience.org/library/papers/31194910 | PubMed |
| 16 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 17 | 40142970 | Anti-Tumor Strategies of Photothermal Therapy Combined with Other Therapies Using Nanoplatforms. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40142970 | PubMed |
| 18 | 39418638 | Applications of Metal-Organic Frameworks (MOFs) in Drug Delivery, Biosensing, and Therapy: A Comprehensive Review. | Langmuir | 2024 | https://conductscience.org/library/papers/39418638 | PubMed |
| 19 | 36386143 | Nanosystems for chemodynamic based combination therapy: Strategies and recent advances. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36386143 | PubMed |
| 20 | 36860309 | Recent progress of hydrogel-based local drug delivery systems for postoperative radiotherapy. | Front Oncol | 2023 | https://conductscience.org/library/papers/36860309 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42644988 | Bioactive Hydrogel-MOF Composites as Resistance-Modulating Wound Interfaces: Molecular Mechanisms and Rational Design for Chronic Wound Management. | Gels | 2026 | https://conductscience.org/library/papers/42644988 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41369447
GET https://conductscience.org/api/papers/v1/41369447/references?page=2